<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04194762</url>
  </required_header>
  <id_info>
    <org_study_id>P.I.: 154/18</org_study_id>
    <nct_id>NCT04194762</nct_id>
  </id_info>
  <brief_title>PARK-FIT. Treadmill vs Cycling in Parkinson´s Disease. Definition of the Most Effective Model in Gait Reeducation</brief_title>
  <official_title>Treadmill vs Cycling in Parkinson´s Disease Rehabilitation. Non-pharmacological, Randomized, Blind Rater, Clinical Trial for the Definition of the Most Effective Model in Gait Reeducation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Puerta de Hierro University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Puerta de Hierro University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PARK-FIT Treadmill vs Cycling in Parkinson´s Disease Rehabilitation. Non-pharmacological
      Clinical Trial for the Definition of the Most Effective Model in Gait Reeducation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treadmill vs Cycling in Parkinson´s Disease Rehabilitation. Non-pharmacological Clinical
      Trial for the Definition of the Most Effective Model in Gait Reeducation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 9, 2019</start_date>
  <completion_date type="Anticipated">July 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>non pharmacological, randomised, double arm intervention. Treadmill training vs cycling training in equal intensity of exercise conditions.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
    <masking_description>Intervention arm for each patient is masked for the raters</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in step length after treadmill training or cycling.</measure>
    <time_frame>Ten months</time_frame>
    <description>Highlight changes in the length of the step after training in treadmill or cycling in patients with Parkinson´s disease.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in step length after treadmill training. Discussion of its specificity to Parkinson´s disease</measure>
    <time_frame>Ten months</time_frame>
    <description>A description of step length and cadence for different velocities of gait after treadmill training.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rating Scale for Gait Evaluation in Parkinson's disease ( RSGE- PD scale )</measure>
    <time_frame>Ten months</time_frame>
    <description>Gait status through the RSGE-PD Scale before and after the intervention.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Movement Disorders Society- Unified Parkinson´s Disease Rating Scale II. (MDS-UPDRS II)</measure>
    <time_frame>Ten months</time_frame>
    <description>Motor functional status through the MDS-UPDRS II Scale before and after the intervention.</description>
  </other_outcome>
  <other_outcome>
    <measure>MDS-UPDRS III</measure>
    <time_frame>Ten months</time_frame>
    <description>Motor examination status through the MDS UPDRS III Scale before and after the intervention</description>
  </other_outcome>
  <other_outcome>
    <measure>The 39-item Parkinson´s Disease Questionnaire (PDQ-39)</measure>
    <time_frame>Ten months</time_frame>
    <description>Quality of life through the PDQ 39 Scale before and after the intervention.,</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>treadmill training</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three training sessions per week for two months of treadmill. The intensity of exercise is monitored through the heart rate (HR). Patients ought to maintain a HR between 40 and 50% of the reserve HR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cycling</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Three training sessions per week for two months of cycling. The intensity of exercise is monitored through the heart rate (HR). Patients ought to maintain a HR between 40 and 50% of the reserve HR</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non pharmacological therapy</intervention_name>
    <description>treadmill training and cycling training in equal intensity exercise.</description>
    <arm_group_label>Cycling</arm_group_label>
    <arm_group_label>treadmill training</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is diagnosed with idiopathic Parkinson's disease according to criteria from
             the United Kingdom Parkinson's Disease Society Brain Bank (UK-PDSBB)

          -  H&amp;Y less than or equal to 2

          -  Stable drug treatment in the six weeks prior to the start of training and during the
             study.

          -  Signature of informed consent.

        Exclusion Criteria:

          -  Diagnosis of other neuro-degenerative disease

          -  Cardiovascular disease or other systemic condition that contraindicates the moderate
             physical exercise

          -  Need for ambulation support

          -  Frequent freezing of gait events.

          -  Mni- Mental State Examination (MMSE) &lt;26
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sabela Novo, MD</last_name>
    <phone>+34 911 91 60 00</phone>
    <email>sabela.novo@salud.madrid.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabela Novo Ponte, MD</last_name>
      <email>sabela.novo@salud.madrid.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>October 13, 2019</study_first_submitted>
  <study_first_submitted_qc>December 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2019</study_first_posted>
  <last_update_submitted>December 10, 2019</last_update_submitted>
  <last_update_submitted_qc>December 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Puerta de Hierro University Hospital</investigator_affiliation>
    <investigator_full_name>Sabela Novo Ponte</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

